Ceritinib (LDK378)

Min.Order / FOB Price:Get Latest Price

1 Gram	FOB Price: USD 10.0000

1 Gram

FOB Price: USD 10.0000

Min.Order :1 Gram
Purity: 99%min.
Payment Terms : L/C,D/A,D/P,T/T,Other

Keywords

Ceritinib LDK378 1032900-25-6

Quick Details

Appearance:White to off-white powder
Application:Ceritinib was used in patients with anaplastic lymphoma kinase positive (ALK +) metastatic non-small cell lung cancer (NSCLC) after crizotinib intolerance or after treatment of crizotinib with exacerb
PackAge:1g/1kg/Al-foiled bag; 25kg/drum
ProductionCapacity:10|Metric Ton|Day
Storage:Room temperature
Transportation:By Air,by courier

Superiority:

LIDE PHARMACEUTICALS LIMITED is a professional chemicals and APIs leading manufacturer in China. Our core business line covers APIs, Intermediates, Herb extract, etc.

We are specialized in chemical synthesis, process development of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and rare chemicals. We also accept custom synthesis project and contract research services.

R&D strength:

We have well equipped chemicals and instrumental laboratories with modern instruments such as HPLC,GC,IR,UV,NMR,LC-MS etc.

At present, we are selling it with good discount for immediate delivery ! BOOKING TO HASTEN !

Details:

(1) Company profile:

Company profile: Lide pharmaceuticals limited

Main products: APIs; Intermediate and other fine chemical products; Piperazine series; Custom Synthesis.

Main Markets: North America; South America; Eastern Europe; Southeast Asia; Africa Oceania; Mid East; Eastern Asia; Western Europe, etc.

(2) Product:

Product Name: Ceritinib (LDK378)

CAS No.: 1032900-25-6

Molecular Formula: C28H36ClN5O3S

Molecular Weight: 558.13514

Appearance: White to off-white powder

Specification: 99%Min.

(3) Application:

Ceritinib was used in patients with anaplastic lymphoma kinase positive (ALK +) metastatic non-small cell lung cancer (NSCLC) after crizotinib intolerance or after treatment of crizotinib with exacerbation.

View All

Visit Store